Response to Letter to the Editor from Chatelain et al.: Weekly Somapacitan is Effective and Well Tolerated in Children with GH Deficiency: The Randomized Phase 3 REAL4 Trial

Response to Letter to the Editor from Chatelain et al.: Weekly Somapacitan is Effective and Well Tolerated in Children with GH Deficiency: The Randomized Phase 3 REAL4 Trial / Miller, Bradley S; Blair, Joanne C; Rasmussen, Michael Højby; Maniatis, Aristides; Kildemoes, Rasmus Juul; Mori, Jun; Polak, Michel; Bang, Rikke Beck; Böttcher, Volker; Stagi, Stefano; Horikawa, Reiko. - In: THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM. - ISSN 0021-972X. - ELETTRONICO. - (2023), pp. 0-0. [10.1210/clinem/dgad095]

Response to Letter to the Editor from Chatelain et al.: Weekly Somapacitan is Effective and Well Tolerated in Children with GH Deficiency: The Randomized Phase 3 REAL4 Trial

Stagi, Stefano;
2023

Abstract

Response to Letter to the Editor from Chatelain et al.: Weekly Somapacitan is Effective and Well Tolerated in Children with GH Deficiency: The Randomized Phase 3 REAL4 Trial
2023
0
0
Miller, Bradley S; Blair, Joanne C; Rasmussen, Michael Højby; Maniatis, Aristides; Kildemoes, Rasmus Juul; Mori, Jun; Polak, Michel; Bang, Rikke Beck; Böttcher, Volker; Stagi, Stefano; Horikawa, Reiko
File in questo prodotto:
File Dimensione Formato  
dgad095.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 201.76 kB
Formato Adobe PDF
201.76 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1302741
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact